Lupus Anticoagulant
otherLupus anticoagulant promotes coronary thrombosis through tissue-factor and coagulation pathway activation.
Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleProthrombotic autoantibody driving in vivo coagulation and coronary thrombosis.
Druggability
Not assessed (no mapped human gene target).
Type I vs non-Type I discrimination
ScoresIndeterminate
R — rupture / Type-I67
C — non-Type-I44
A — assay feasibility45
E — evidence strength65
T1DI (composite)18
Specificity differential (R−C)+22.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 1
2hypovolemia / dehydrationmag 1
2tachyarrhythmiamag 1
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 1
2high-demand / peri-operative stressmag 1
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosismag 2
4cin-stent restenosismag 1
5CABG-relatedn/a
Coverage: 9/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 23 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Method depends on analyte chemistry
Reagent / substrate
Analyte-specific
Platform
Variable
Turnaround · availability
Research · Research
Literature evidence(1)
- Antiphospholipid antibodies in young myocardial infarction patients.Indian journal of biochemistry & biophysics · 2007 · PMID 18320848